---
freshness:
  last-reviewed: 2026-02-05
  data-year: 2025
  review-cycle: 6
  sections:
    - name: "NIH Budget and Funding Landscape"
      data-year: 2025
    - name: "Clinical Trial Landscape"
      data-year: 2025
    - name: "Drug Development Pipeline"
      data-year: 2024-2025
    - name: "Biomedical Workforce"
      data-year: 2024
notes:
  - Revisit NIH appropriations after FY2026 budget is enacted.
  - Monitor ongoing NIH structural reform proposals.
  - Update drug development cost estimates as new Tufts CSDD or similar analyses are published.
sources:
  count: 12
  verified: 2026-02-05
  broken: 0
---

# Biomedical Research: Current State

## NIH Budget and Funding Landscape

### Overall Budget

The NIH budget has grown nominally in recent years but faces persistent challenges in real-dollar purchasing power. After the historic doubling from $13.6 billion to $27.2 billion between FY1998 and FY2003, funding stagnated for over a decade in inflation-adjusted terms. Sequestration in FY2013 cut NIH by $1.6 billion, and while subsequent Congresses have approved increases, the purchasing power of the NIH budget has only recently recovered to pre-sequestration levels when adjusted for biomedical research inflation (which runs higher than general CPI).

| Fiscal Year | NIH Budget (nominal) | Approximate Real-Dollar Change |
|-------------|---------------------|-------------------------------|
| FY2003 | $27.2 billion | Peak of doubling |
| FY2013 | $29.2 billion (post-sequester: $27.6B) | Below FY2003 in real terms |
| FY2020 | $41.7 billion | Recovery; COVID supplements added |
| FY2023 | $47.5 billion | Nominal growth, BRDPI-adjusted lag |
| FY2025 | ~$48.3 billion | Modest real increase |

### Institute Breakdown

The 27 NIH institutes and centers vary enormously in size and mission. The top five by budget account for roughly half of all NIH spending.

| Institute/Center | FY2025 Budget (approx.) | Primary Focus |
|-----------------|------------------------|---------------|
| National Cancer Institute (NCI) | $7.3 billion | Cancer research, treatment, prevention |
| National Institute of Allergy and Infectious Diseases (NIAID) | $6.3 billion | Infectious disease, immunology, vaccines |
| National Heart, Lung, and Blood Institute (NHLBI) | $3.9 billion | Cardiovascular, pulmonary, blood diseases |
| National Institute of General Medical Sciences (NIGMS) | $3.3 billion | Basic biomedical research, training |
| National Institute of Neurological Disorders and Stroke (NINDS) | $2.8 billion | Neurological disease and stroke |

### Funding Success Rates

The probability that a submitted research project grant (RPG) application will be funded has declined sharply over the past two decades.

| Period | RPG Success Rate | R01 Success Rate | Applications Submitted |
|--------|-----------------|-----------------|----------------------|
| 1998-2003 (doubling era) | ~30% | ~30% | ~25,000/year |
| 2004-2012 (post-doubling) | ~20-22% | ~18-22% | ~35,000/year |
| 2013-2015 (sequestration era) | ~17-18% | ~16-18% | ~50,000/year |
| 2020-2025 (current) | ~20-21% | ~20% | ~55,000+/year |

The number of applications has roughly doubled while budgets (in real terms) have not kept pace, creating intense competition. A principal investigator may need to submit 4-5 applications to secure a single funded grant.

### Indirect Costs (Facilities and Administrative Rates)

Universities negotiate indirect cost rates with the federal government to cover research infrastructure, administration, and facilities. These rates are a major and controversial component of research spending.

| Institution Type | Typical F&A Rate | What It Covers |
|-----------------|-----------------|----------------|
| Research-intensive universities | 50-65% of direct costs | Facilities, administration, utilities, compliance |
| Medical schools | 55-70% of direct costs | Clinical research infrastructure, regulatory compliance |
| Teaching-focused institutions | 30-50% of direct costs | More limited research infrastructure |

At a 60% indirect cost rate, a $500,000 direct-cost grant costs NIH $800,000 total, with $300,000 going to institutional overhead rather than research activities. Critics argue these rates are inflated and divert funds from science; universities counter that rates do not fully cover actual costs.

## Clinical Trial Landscape

### Scale and Structure

The United States conducts more clinical trials than any other country, with over 130,000 trials registered on ClinicalTrials.gov as active or recruiting at any given time. However, the clinical trial enterprise faces significant challenges.

| Metric | Current Status |
|--------|---------------|
| Active registered trials (U.S.) | ~130,000+ |
| NIH-funded clinical trials | ~7,000 active |
| Average Phase III trial cost | $20-50 million |
| Average time from Phase I to approval | 8-12 years |
| Patient enrollment meeting timeline targets | ~20% of trials |
| Trials terminated for enrollment failure | ~20% |
| Trial participants from minority populations | ~15-25% (vs. ~40% of U.S. population) |

### Enrollment Challenges

Clinical trial recruitment remains one of the most persistent bottlenecks. Fewer than 5% of adult cancer patients enroll in clinical trials. Rural and minority populations are severely underrepresented.

**Barriers to enrollment:**

- Geographic distance from trial sites (concentrated at academic medical centers)
- Lack of awareness about available trials
- Strict eligibility criteria that exclude real-world patient populations
- Financial burden on participants (travel, time off work, uncovered costs)
- Historical mistrust, particularly among Black Americans (legacy of Tuskegee)
- Language barriers and limited culturally competent outreach

### Decentralized and Adaptive Trials

The COVID-19 pandemic accelerated adoption of decentralized trial elements, including remote monitoring, telehealth visits, and direct-to-patient drug delivery. The FDA has issued guidance supporting these approaches, but adoption remains uneven.

## Drug Development Pipeline

### Costs and Timelines

The cost of developing a new drug has been the subject of intense debate, with estimates varying widely depending on methodology.

| Estimate Source | Cost per Approved Drug | Methodology |
|----------------|----------------------|-------------|
| Tufts CSDD (2014, updated) | $2.6 billion | Includes failures and cost of capital |
| JAMA Internal Medicine (2020) | $985 million median | 63 FDA-approved drugs, out-of-pocket only |
| Deloitte (2023) | $2.3 billion | Industry survey, includes cost of capital |

Regardless of the exact figure, drug development is extremely expensive, and costs have been rising faster than inflation for decades. The average timeline from target identification to FDA approval is 10-15 years.

### Attrition Rates

Most drug candidates fail during development. The overall probability of a drug entering Phase I trials and ultimately receiving FDA approval is approximately 10%.

| Development Phase | Success Rate (to next phase) | Cumulative Success |
|-------------------|-----------------------------|--------------------|
| Preclinical to Phase I | ~40-60% | ~50% |
| Phase I to Phase II | ~60-70% | ~35% |
| Phase II to Phase III | ~30-40% | ~12% |
| Phase III to FDA filing | ~60-70% | ~8% |
| FDA filing to approval | ~85-90% | ~7-10% |

### Pharma vs. Public Funding

The relationship between public and private research investment is complex. NIH funds the majority of basic research, while industry dominates later-stage development.

| Funding Source | Annual Investment | Focus Areas |
|----------------|-------------------|-------------|
| NIH | ~$48 billion | Basic and early translational research |
| Pharmaceutical industry (global R&D) | ~$250+ billion | Late-stage development, clinical trials, regulatory |
| Other federal agencies (DoD, VA, NSF) | ~$8-10 billion | Specialized biomedical applications |
| Foundations and nonprofits | ~$8-10 billion | Disease-specific research |
| State governments | ~$2-3 billion | Stem cell, cancer, institution-specific |

Industry has increasingly pulled back from early-stage and basic research, focusing on less risky late-stage development and acquisitions of smaller companies with promising candidates. This retreat widens the "valley of death" between academic discovery and commercial development.

## COVID-Era Impacts

### Operation Warp Speed and BARDA

The federal government's COVID-19 vaccine development effort demonstrated that compressed development timelines are possible with sufficient funding, regulatory flexibility, and pre-existing scientific foundations (mRNA technology had been in development for over a decade with NIH support).

**Lessons learned:**

- Parallel processing (manufacturing during trials) can dramatically compress timelines
- Advanced market commitments reduce industry financial risk
- Platform technologies (mRNA, viral vectors) enable rapid adaptation
- Public-private partnerships can be highly effective when properly structured
- Pre-pandemic basic research investment was essential to rapid response

### Pandemic Effects on NIH-Funded Research

- **Lab shutdowns**: Most non-COVID NIH-funded research was disrupted for 3-12 months
- **No-cost extensions**: NIH provided widespread extensions but limited supplemental funding
- **Career disruption**: Early-career researchers and trainees disproportionately affected
- **Pivot to COVID**: Many researchers redirected efforts, sometimes at the expense of core programs
- **Mental health**: Researcher burnout and isolation became significant workforce concerns

## Biomedical Workforce

### Training Pipeline

The biomedical research workforce operates on a model that produces far more trainees than the system can absorb into traditional research careers.

| Career Stage | Number (approx.) | Median Duration | Median Compensation |
|-------------|------------------|----------------|-------------------|
| Graduate students (biomedical) | ~90,000 | 5-7 years | $35,000-40,000 (stipend) |
| Postdoctoral researchers | ~60,000-70,000 | 4-6 years | $56,000-70,000 |
| Tenure-track faculty | ~30,000 | Permanent (if tenured) | $100,000-200,000+ |
| Tenured faculty | ~25,000 | Until retirement | $120,000-300,000+ |

Only about 15-20% of biomedical PhDs ultimately secure tenure-track faculty positions. The rest find careers in industry, government, teaching, science policy, or leave research entirely. Many report feeling that their training inadequately prepared them for these alternative paths.

### Diversity and Representation

The biomedical research workforce does not reflect the diversity of the U.S. population, and disparities are particularly stark at senior levels.

| Demographic | Share of U.S. Population | Share of NIH R01 PIs |
|-------------|------------------------|--------------------|
| White | 58% | ~75% |
| Asian | 6% | ~17% |
| Black/African American | 13% | ~2-3% |
| Hispanic/Latino | 19% | ~4-5% |
| Women | 51% | ~35% (improving) |

Black scientists receive NIH R01 grants at significantly lower rates than White scientists even after controlling for institution, training, and publication record. NIH has implemented several programs to address these disparities, including the UNITE initiative and the Faculty Institutional Recruitment for Sustainable Transformation (FIRST) program, but progress has been slow.

### Brain Drain and Retention

Low postdoctoral salaries, long training periods, and uncertain career prospects are driving talented scientists away from research. International scientists, who comprise a significant portion of the U.S. biomedical workforce, face additional challenges with immigration policy and visa uncertainty.

## Recent Developments

### ARPA-H (Advanced Research Projects Agency for Health)

Established in 2022 and funded at approximately $2.5 billion, ARPA-H is modeled on DARPA and aims to fund high-risk, high-reward health research that falls outside traditional NIH mechanisms. Early programs focus on cancer detection, pandemic preparedness, and health equity technologies.

### 21st Century Cures Act Implementation

The 2016 legislation continues to shape the research landscape through provisions on:

- Real-world evidence in drug approvals
- Regenerative medicine advanced therapy designation
- NIH Innovation Fund
- Precision Medicine Initiative (All of Us Research Program)

### NIH Data Management and Sharing Policy

Effective January 2023, NIH now requires all funded researchers to submit data management and sharing plans with their grant applications. The policy aims to increase transparency and reproducibility but has generated concerns about compliance burden, particularly for smaller labs.

### Artificial Intelligence in Biomedical Research

AI and machine learning are rapidly transforming drug discovery, protein structure prediction (AlphaFold), medical imaging, and clinical trial design. NIH has launched the Bridge2AI program and other initiatives to build AI-ready datasets and train researchers in computational methods.

---

## Document Navigation

- Previous: [Overview](01-overview.md)
- Next: [History](03-history.md)
